ClinicalTrials.gg
CompletedNCT07586423Updated May 14, 2026

Effect of Virtual Reality on Pain, Anxiety and Vital Signs During Diabetic Foot Care

An interventional study of VR and Standard Diabetic Foot Care in Diabetic Foot Ulcer, sponsored by Malatya Turgut Ozal University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-14.

Sponsored by Malatya Turgut Ozal University · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Registered 1 year 4 months after the study started (first participant enrolled Dec 2024, registered Apr 2026).
Phase
Not applicable
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study aims to determine the effects of a virtual reality (VR) intervention on pain level, state anxiety, and vital signs during foot care in individuals with diabetic foot ulcers. The study was designed as a randomized controlled trial and includes 64 individuals with diabetes (intervention=32, control=32). The intervention group will receive VR during diabetic foot care, while the control group will receive standard care. Data will be collected at pre-test and post-test using the Demographic Information Form, Vital Signs Form, State-Trait Anxiety Inventory (STAI), and Visual Analog Scale (VAS) for pain. Data analysis will be performed using SPSS 22.0.

02

Conditions studied

  • Diabetic Foot Ulcer

Keywords

  • Virtual reality
  • Diabetic foot
  • Nursing
  • Pain
  • Anxiety
  • Vital signs
03

In context

Diabetic Foot

1,077 studies on the registry are indexed under Diabetic Foot; 222 are open to participants now.

This study's enrollment of 64 is close to the median of 60 across 847 interventional studies indexed under Diabetic Foot.

Browse Diabetic Foot studies →

Lead sponsor

Malatya Turgut Ozal University is the lead sponsor of 9 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years and older Diagnosis of Type 2 Diabetes Mellitus Diabetic foot ulcer classified as Wagner stage 3 or 4 No mental or physical condition that would interfere with communication or participation No visual or hearing impairment Ability to understand and speak Turkish Willingness to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Presence of chronic wounds other than diabetic foot ulcer (e.g., arterial or venous ulcers) Age under 18 years
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    Intervention Group (VR Group)

    Participants received virtual reality (VR) intervention during diabetic foot care procedures in addition to standard care. VR was used as a non-pharmacological distraction method during the procedure.

    Other: VR · Other: Standard Diabetic Foot Care

  • Active comparator
    Control Group

    Participants received standard diabetic foot care without virtual reality intervention.

    Other: Standard Diabetic Foot Care

Interventions

  • OtherVR

    Participants in the intervention group received virtual reality (VR) exposure during diabetic foot care procedures. A virtual reality headset was used as a non-pharmacological distraction method to reduce pain and anxiety. The VR intervention was applied during the procedure in addition to standard diabetic foot care. Vital signs such as blood pressure, pulse rate, respiratory rate, oxygen saturation, and body temperature were monitored before and after the procedure to evaluate physiological responses.

    Also known as: VR GLASSES, Standard Diabetic Foot Care

  • OtherStandard Diabetic Foot Care

    Participants in the control group received standard diabetic foot care according to institutional protocols, without any virtual reality intervention. Vital signs including blood pressure, pulse rate, respiratory rate, oxygen saturation, and body temperature were monitored before and after the procedure.

06

What researchers measure

Primary outcomes

  1. Change in Pain Level

    Pain intensity measured using the Visual Analog Scale (VAS), a 10 cm horizontal line anchored at 0 (no pain) and 10 (worst imaginable pain). Higher scores indicate greater pain. Change is calculated as post-test score minus pre-test score.

    Time frame: Pre-test: approximately 5 minutes before foot care; Post-test: within 0-2 minutes after completion of foot care

Secondary outcomes

  1. Change in State Anxiety

    State anxiety measured using the State subscale of the State-Trait Anxiety Inventory (STAI-I), a validated 20-item self-report scale scored 20-80. Higher scores indicate greater anxiety. Change is calculated as post-test score minus pre-test score.

    Time frame: Pre-test: approximately 5 minutes before foot care; Post-test: within 0-2 minutes after completion of foot care

Other outcomes

  1. Change in Body Temperature

    Body temperature (°C) measured using a non-contact infrared thermometer (Life Net Medical JA-11C). Change is calculated as post-test value minus pre-test value.

    Time frame: Pre-test: approximately 5 minutes before foot care; Post-test: within 0-2 minutes after completion of foot care

  2. Change in Oxygen Saturation (SpO₂)

    Peripheral oxygen saturation (SpO₂, %) measured using a fingertip pulse oximeter (Life Net Medical PFX033). Change is calculated as post-test value minus pre-test value.

    Time frame: Pre-test: approximately 5 minutes before foot care; Post-test: within 0-2 minutes after completion of foot care

  3. Change in Pulse Rate

    Pulse rate (beats per minute) measured using a fingertip pulse oximeter (Life Net Medical PFX033). Change is calculated as post-test value minus pre-test value.

    Time frame: Pre-test: approximately 5 minutes before foot care; Post-test: within 0-2 minutes after completion of foot care

  4. Change in Respiratory Rate

    Respiratory rate (breaths per minute) assessed by direct observation and counting by the researcher. Change is calculated as post-test value minus pre-test value.

    Time frame: Pre-test: approximately 5 minutes before foot care; Post-test: within 0-2 minutes after completion of foot care

  5. Change in Systolic Blood Pressure

    Systolic blood pressure (mmHg) measured using an upper-arm automated sphygmomanometer (Omron M3 Comfort HEM-7155-E) after the participant had been seated and resting for at least 5 minutes. Change is calculated as post-test value minus pre-test value.

    Time frame: Pre-test: approximately 5 minutes before foot care; Post-test: within 0-2 minutes after completion of foot care

  6. Change in Diastolic Blood Pressure

    Diastolic blood pressure (mmHg) measured using an upper-arm automated sphygmomanometer (Omron M3 Comfort HEM-7155-E) after the participant had been seated and resting for at least 5 minutes. Change is calculated as post-test value minus pre-test value.

    Time frame: Pre-test: approximately 5 minutes before foot care; Post-test: within 0-2 minutes after completion of foot care

07

Study locations

1 site
  • Malatya Turgut Özal University Training and Research Hospital
    Malatya, Malatya 4400, Turkey (Türkiye)
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared due to patient privacy and confidentiality concerns. The data are collected within a single institutional clinical study for academic thesis purposes and are not planned for public data sharing.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07586423
Lead sponsor
Malatya Turgut Ozal University
Responsible party
Yasemin Özkul (Master's Student, Malatya Turgut Ozal University) — Principal investigator
First posted
May 14, 2026
Start date
Dec 9, 2024
Primary completion
Jun 15, 2025
Completion
Jun 15, 2025
Last update
May 14, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion